NHAS
Novo Holdings A/S Portfolio holdings
AUM
$1.55B
1-Year Est. Return
16.8%
1 Year Est. Return
+16.8%
AUM
$1.55B
AUM Growth
+$135M
(+9.5%)
Holding
30
Top Buys
| 1 | +$22.7M | |
| 2 | +$7M | |
| 3 | +$3.12M | |
| 4 |
Apogee Therapeutics
APGE
|
+$2.01M |
| 5 |
ArriVent BioPharma
AVBP
|
+$1.29M |
Top Sells
| 1 | +$69.1M | |
| 2 | +$34M | |
| 3 | +$20.6M | |
| 4 |
ASML
ASML
|
+$19.4M |
| 5 |
Mirum Pharmaceuticals
MIRM
|
+$17.3M |
Sector Composition
| 1 | Healthcare | 50.22% |
| 2 | Technology | 14.29% |
| 3 | Financials | 10.3% |
| 4 | Consumer Discretionary | 2.96% |
| 5 | Industrials | 0.25% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
1
Vanguard Total Stock Market ETF
VTI
$567B
| $341M | 21.97% |
1,038,550
|
|
||
2
Brookfield
BN
$105B
| $160M | 10.3% |
3,496,245
|
|
||
|
3
ASML
ASML
$427B
| $141M | 9.1% |
145,836
-20,000
|
|
||
|
4
Mirum Pharmaceuticals
MIRM
$3.52B
| $92.7M | 5.97% |
1,264,028
-236,027
|
|
||
5
Edgewise Therapeutics
EWTX
$2.5B
| $86.8M | 5.59% |
5,350,000
|
|
||
6
Salesforce
CRM
$248B
| $78.3M | 5.04% |
330,187
|
|
||
7
Merus
MRUS
$7.29B
| $70.6M | 4.55% |
750,000
|
|
||
8
Crinetics Pharmaceuticals
CRNX
$4.43B
| $67.7M | 4.36% |
1,625,000
+75,000
|
|
||
9
Viridian Therapeutics
VRDN
$3.06B
| $51.4M | 3.31% |
2,380,000
|
|
||
10
Alibaba
BABA
$378B
| $46M | 2.96% |
257,327
-115,000
|
|
||
|
ZBIO
11
Zenas BioPharma
ZBIO
$2.11B
| $44.4M | 2.86% |
2,000,000
-250,000
|
|
||
12
Pharvaris
PHVS
$1.72B
| $43.7M | 2.81% |
1,750,000
+25,000
|
|
||
13
Recursion Pharmaceuticals
RXRX
$2.45B
| $38.7M | 2.49% |
7,929,835
-1,735,293
|
|
||
|
14
ArriVent BioPharma
AVBP
$1.02B
| $35.8M | 2.31% |
1,942,142
+70,000
|
|
||
15
BioMarin Pharmaceuticals
BMRN
$10.3B
| $35.7M | 2.3% |
660,000
|
|
||
16
Vaxcyte
PCVX
$6.08B
| $33M | 2.13% |
916,160
|
|
||
17
Celldex Therapeutics
CLDX
$1.96B
| $31M | 2% |
1,200,000
|
|
||
18
Enliven Therapeutics
ELVN
$1.29B
| $29.2M | 1.88% |
1,426,260
+341,828
|
|
||
19
Insmed
INSM
$43.5B
| $28.8M | 1.86% |
200,000
-480,000
|
|
||
|
VALN
20
Valneva
VALN
$765M
| $28.6M | 1.84% |
2,345,000
-30,000
|
|
||
|
BBOT
21
BridgeBio Oncology
BBOT
$1.1B
| $22.7M | 1.46% |
+1,961,317
|
|
||
|
22
Apogee Therapeutics
APGE
$5.24B
| $19.9M | 1.28% |
500,000
+50,608
|
|
||
23
4D Molecular Therapeutics
FDMT
$611M
| $17.4M | 1.12% |
2,000,000
|
|
||
24
LanzaTech
LNZA
$35M
| $3.88M | 0.25% |
158,148
|
|
||
25
Marqeta
MQ
$2.05B
| $2.33M | 0.15% |
441,558
|
|